SCHEMBL5729940

SCHEMBL5729940

CN1CCC(C#N)(c2ccccc2F)CC1

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.52
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566348 1.00 OPRM1 (0.52) OPRM1KMT2A
Hydrochloric Acid SCHEMBL3597155 0.98 OPRM1 (0.55) OPRM1KMT2A
SCHEMBL30929543 0.84 HDAC4 (0.41) OPRM1
SCHEMBL1769351 0.84 HDAC4 (0.41) OPRM1
SCHEMBL6887165 0.83 OPRM1 (0.46) OPRM1
SCHEMBL11095063 0.83 KMT2A (0.39) OPRM1KMT2A
SCHEMBL11094082 0.83 OPRM1 (0.50) OPRM1KMT2A
SCHEMBL6884854 0.82 OPRM1 (0.56) OPRM1KMT2A
SCHEMBL625354 0.80 NPC1 (0.44) OPRM1KMT2A
SCHEMBL1020368 0.80 NPC1 (0.48) OPRM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380735-A Method for synthesizing fluorene and indeno [2,1-b ] indolyl spiro indole 河南师范大学 2022-04-22 CN disclosed
CN-101671310-A Compounds and compositions useful as cathepsin s inhibitors NOVARTIS AG 2010-03-17 CN disclosed
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS PFIZER INC. 2008-12-18 US disclosed
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 US disclosed
CN-101035768-A Compounds and compositions as cathepsin S inhibitors NOVARTIS AG (CH) 2007-09-12 CN disclosed
EP-1372653-B1 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2006-10-04 EP disclosed
US-20060204436-A1 Tritiated growth hormone secretagogue mk-0677 F. HOFFMANN-LA ROCHE AG (CH) 2006-09-14 US disclosed
CN-1812815-A Tritiated growth hormone secretagogue MK-0677 HOFFMANN LA ROCHE (CH) 2006-08-02 CN disclosed
EP-1641494-A1 TRITIATED GROWTH HORMONE SECRETAGOGUE MK-0677 F. HOFFMANN-LA ROCHE AG (CH) 2006-04-05 EP disclosed
US-7015235-B2 Acylated piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2006-03-21 US disclosed
US-20040097546-A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists MERCK SHARP & DOHME CORP. 2004-05-20 US disclosed
EP-1372653-A2 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS Merck & Co., Inc. (US) 2004-01-02 EP disclosed
WO-2002068387-A2 ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO., INC. (US) 2002-09-06 WO disclosed
US-4477667-A Spiro[indoline-3,4'-piperidine]s and related compounds AMERICAN HOECHST CORPORATION (US) 1984-10-16 US disclosed
US-4408050-A Spiro(indoline-3,4'-piperidine) and related compounds AMERICAN HOECHST CORPORATION (US) 1983-10-04 US disclosed
US-4379932-A Process for preparing spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1983-04-12 US disclosed
US-4379933-A Process for preparing spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1983-04-12 US disclosed
US-4345081-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1982-08-17 US disclosed
US-4307235-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1981-12-22 US disclosed
US-4209625-A Spiro[indoline-3,4'-piperidine]s AMERICAN HOECHST CORPORATION (US) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 OPRM1 1548/4885KMT2A 3751/4885
US-20060204436-A1 Tritiated growth hormone secretagogue mk-0677 GHSR, GHRHR, TRHR OPRM1 2300/4885KMT2A 2256/4885
US-20040097546-A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists MC4R, MC5R, MC3R OPRM1 77/4885KMT2A 671/4885
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS AZI2, PAICS, UGT2B7 OPRM1 2171/4885KMT2A 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.